Propanc Biopharma Raises up to $100 Million through Private Placement with Hexstone Capital

Propanc Biopharma has secured up to $100 million in a private placement of convertible preferred stock from Hexstone Capital. The funds will be used to support the company's digital asset initiatives. The deal includes a $50 million initial investment and an option for Hexstone to invest an additional $50 million.